James Lewis, MD, MSCE
|Office Location||720, Blockley Hall|
|Office Phone||(215) 573-5137|
|CCEB Appointment||Senior Scholar, Epidemiology|
|Primary Faculty Appointment||Professor of Medicine, Gastroenterology Division, University of Pennsylvania SOM|
|DBE Appointment||Professor of Epidemiology|
Senior Fellow, Leonard Davis Institute
Associate Director, Inflammatory Bowel Disease Program
Dr. Lewis earned a BA in Interdisciplinary Studies from the University of Virginia in 1987. He received his MD degree from the University of Pennsylvania in 1991. He completed a residency in Internal Medicine and subsequently served as Chief Medical Resident at Yale University. Following his residency, Dr. Lewis simultaneously completed a fellowship in Gastroenterology and a Master's program in Clinical Epidemiology at the University of Pennsylvania. He joined the faculty at the University of Pennsylvania in 1998 and currently is a Professor of Medicine and Epidemiology, Senior Scholar at the Center for Clinical Epidemiology and Biostatistics, and Senior Fellow in the Leonard Davis Institute of Health Economics. He is the Associate Director of the Inflammatory Bowel Disease Program at the University of Pennsylvania.
Dr. Lewis conducts clinical research related to inflammatory bowel disease, medication safety, and optimizing medical therapies. Examples include a series of studies investigating whether patients treated with azathioprine are at increased risk to develop lymphoma, retrospective cohort studies examining the association of inflammatory bowel disease with viral infections and neurologic diseases, retrospective cohort studies identifying subpopulations of IBD patients at increased risk of mortality, and clinical trials using the PPARγ ligand rosiglitazone to treat ulcerative colitis, using biomarkers to adjust medical therapies, and to investigate the effect of diet on the gut microbiome. He also has conducted a variety of studies to advance the methods of conducting clinical trials for inflammatory bowel disease therapies and for conducting retrospective cohort studies using electronic medical records data.
Dr. Lewis previously served as an Associate Editor for two journals, Gastroenterology and Pharmacoepidemiology and Drug Safety. He is currently the Chair of the Crohn’s and Colitis Foundation of America's National Scientific Advisory Committee.
EP 510 - Introductory Epidemiology
Lewis JD, Asch DA.: Barriers to office-based screening sigmoidoscopy: does reimbursement cover costs? Annals of Internal Medicine. 130: 525-30 (1999).
Lewis JD, Brown A, Schwartz JS.: Initial evaluation of rectal bleeding in young persons: A cost-effectiveness analysis. Annals of Internal Medicine. 136: 99-110 (2002).
Yang YX, Lewis JD, Epstein S, Metz DC. Chronic proton pump inhibitor therapy and hip fracture risk. JAMA. 296:2947-53 (2006).
Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology.118: 1018-24 (2000).
Lewis JD (3), Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 121:1080-7 (2001).
Kandiel A, Fraser AJ, Korelitz BI, Brensinger C, Lewis JD. Increased Risk of Lymphoma among Inflammatory Bowel Disease Patients Treated with Azathioprine and 6-Mercaptopurine. Gut. 54:1121-5 (2005).
Gupta G, Gelfand JM, Lewis JD. Increased risk of demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 129:819-26 (2005).
Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL: Immunosuppression medications and mortality in inflammatory bowel disease. American Journal of Gastroenterology. 103: 1428-35 (2008).
Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JE, Nessel L, Wu GD. Rosiglitazone for ulcerative colitis: a placebo-controlled trial. Gastroenterology. 134:688-95 (2008).
Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP Jr., Habel LA: Thiazolidinedione Therapy Is Not Associated with Increased Colonic Neoplasia Risk in Patients with Diabetes Mellitus. Gastroenterology. 135: 1914-23 (2008).